StockData
Vistagen Therapeutics, Inc. logo

Vistagen Therapeutics, Inc. (VTGN) stock

VTGNNasdaqPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 9/3078% below fair value
$0.19+0.00 (+2.01%)

Close on Nov 17, 2026Market cap $8.34MP/E –Yield –

Vistagen Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Vistagen Therapeutics's price to book ratio was 0.3× on Nov 11, 2026, against 2.4× a year earlier. Over the last 5 years it ranged from 0.2× to 5.5×, with a median of 0.9×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20260.3×−0.0
2025Dec 31, 20250.3×−0.6
2024Dec 31, 20241.0×−0.2
2023Dec 29, 20231.1×+0.4
2022Dec 30, 20220.7×−3.0
2021Dec 31, 20213.7×−20.3
2020Dec 31, 202024.0×+0.6
2019Oct 31, 201923.3×+15.3
2018Dec 31, 20188.0×−17.0
2017Jul 31, 201725.1×+23.5
2016Dec 30, 20161.6×–

More Vistagen Therapeutics figures

See a number that looks wrong?